Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer
The purpose of this study is to determine the clinical efficacy and toxicity of High-dose rate (HDR) brachytherapy as monotherapy for the treatment of low risk and intermediate risk prostate cancer.
Prostate Cancer
RADIATION: HDR brachytherapy monotherapy
Disease-free survival, Disease free survival as evaluated by absence of biochemical recurrence (Phoenix criteria) and absence of clinically/radiologically diagnosed local, regional or distant recurrence., 5 years
Genito-urinary (GU) toxicity, Toxicity according to International prostate symptom score (IPSS) and Expanded Prostate Index Composite (EPIC) questionnaires., 6 weeks, 2 years and 5 years post treatment
Overall survival, 5 years|Gastro-Intestinal (GI) Toxicity, Toxicity according to Expanded Prostate Index Composite (EPIC) questionnaires., 6 weeks, 2 years and 5 years post treatment
The purpose of this study is to determine the clinical efficacy and toxicity of High-dose rate (HDR) brachytherapy as monotherapy for the treatment of low risk and intermediate risk prostate cancer.